Literature DB >> 12577148

Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study.

Stijn Blot1, Koenraad Vandewoude, Francis Colardyn.   

Abstract

OBJECTIVE: To determine outcome and attributable mortality in critically ill patients with nosocomial bacteremia involving A. baumannii.
DESIGN: A retrospective matched cohort study in which all ICU patients with microbiologically documented A. baumannii bacteremia were defined as cases. Matching of the controls was based on equivalent APACHE II score (+/-2 points) and diagnostic category. Control patients were required to have an ICU stay equivalent to or longer than the case prior to onset of the bacteremia.
SETTING: The 54-bed ICU of the 1060-bed Ghent University Hospital. PATIENTS: 45 ICU patients with A. baumannii bacteremia and 90 matched control subjects without clinical or microbiological evidence of blood stream infection. MEASUREMENTS: Population characteristics and in-hospital mortality rates of patients with A. baumannii bacteremia and their controls were compared. Attributable mortality is determined by subtracting the crude mortality rate of the controls from the crude mortality rate of the cases.
RESULTS: Patients with A. baumannii bacteremia had significantly more hemodynamic instability, longer ICU stay, and longer length of ventilator dependence than controls. In-hospital mortality rates for cases and controls were, respectively, 42.2% and 34.4%; thus the attributable mortality was 7.8%.
CONCLUSION: In critically ill patients A. baumannii bacteremia is not associated with a significantly increased mortality rate.

Entities:  

Mesh:

Year:  2003        PMID: 12577148     DOI: 10.1007/s00134-003-1648-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

1.  Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study.

Authors:  Pierre Moine; Jean-François Timsit; Arnaud De Lassence; Gilles Troché; Jean-Philippe Fosse; Corrine Alberti; Yves Cohen
Journal:  Intensive Care Med       Date:  2002-01-16       Impact factor: 17.440

2.  The mortality of hospital-acquired bloodstream infections: need for a new vital statistic?

Authors:  R P Wenzel
Journal:  Int J Epidemiol       Date:  1988-03       Impact factor: 7.196

3.  Evaluation of outcome of intravenous catheter-related infections in critically ill patients.

Authors:  J Rello; A Ochagavia; E Sabanes; M Roque; D Mariscal; E Reynaga; J Valles
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

4.  Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults.

Authors:  S M Poutanen; M Louie; A E Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

5.  Acinetobacter bacteremia in Hong Kong: prospective study and review.

Authors:  H Siau; K Y Yuen; P L Ho; S S Wong; P C Woo
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

6.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

7.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D Pittet; D Tarara; R P Wenzel
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

8.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.

Authors:  Manuel Iregui; Suzanne Ward; Glenda Sherman; Victoria J Fraser; Marin H Kollef
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

9.  Clinical impact of nosocomial Klebsiella bacteremia in critically ill patients.

Authors:  S I Blot; K H Vandewoude; F A Colardyn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-06-12       Impact factor: 3.267

10.  Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Arch Intern Med       Date:  2002-10-28
View more
  38 in total

1.  Invasive devices: no need? No use!

Authors:  Stijn I Blot; Renaat Peleman; Koenraad H Vandewoude
Journal:  Intensive Care Med       Date:  2006-12-05       Impact factor: 17.440

Review 2.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

3.  Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.

Authors:  M-C Chiang; S-C Kuo; S-J Chen; S-P Yang; Y-T Lee; T-L Chen; C-P Fung
Journal:  Infection       Date:  2011-09-02       Impact factor: 3.553

4.  Trauma is associated with a better prognosis in intensive care patients with Acinetobacter infections.

Authors:  A C Tonacio; M S Oliveira; L M S Malbouisson; A S Levin
Journal:  Infection       Date:  2013-10-30       Impact factor: 3.553

Review 5.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  Toward a structome of Acinetobacter baumannii drug targets.

Authors:  Logan M Tillery; Kayleigh F Barrett; David M Dranow; Justin Craig; Roger Shek; Ian Chun; Lynn K Barrett; Isabelle Q Phan; Sandhya Subramanian; Jan Abendroth; Donald D Lorimer; Thomas E Edwards; Wesley C Van Voorhis
Journal:  Protein Sci       Date:  2020-01-20       Impact factor: 6.725

7.  Risk Factors and Outcomes Associated with Multidrug-Resistant Acinetobacter baumannii upon Intensive Care Unit Admission.

Authors:  Natalia Blanco; Anthony D Harris; Clare Rock; J Kristie Johnson; Lisa Pineles; Robert A Bonomo; Arjun Srinivasan; Melinda M Pettigrew; Kerri A Thom
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance.

Authors:  D W Wareham; D C Bean; P Khanna; E M Hennessy; D Krahe; A Ely; M Millar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-19       Impact factor: 3.267

9.  Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.

Authors:  Rebecca H Sunenshine; Marc-Oliver Wright; Lisa L Maragakis; Anthony D Harris; Xiaoyan Song; Joan Hebden; Sara E Cosgrove; Ashley Anderson; Jennifer Carnell; Daniel B Jernigan; David G Kleinbaum; Trish M Perl; Harold C Standiford; Arjun Srinivasan
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

Review 10.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.